In 2018 Morelos had the highest per capita concentration of researchers nationwide, with a rate of 100 researchers per 100,000 inhabitants; The entity is home to the most important research centers, which have generated, among other things, highly relevant inventions for the daily lives of citizens.
Morelos has one of the pioneering centers within the Mexican Social Security Institute (IMSS) in the production of scientific articles and inventions that have been successfully patented, the Centro de Investigación Biomédica del Sur (CIBIS), located in Xochitepec, until currently has 24 patents granted.
The CIBIS is one of the five strategic centers that the IMSS has distributed throughout the country to carry out its biomedical research; Since 1985 its mission has been to generate scientific knowledge in the areas of Pharmacology, Phytochemistry, Biotechnology, Pharmaceutical Technology and Medicine for the development of safe and effective drugs in the treatment of the most frequent diseases in Mexican society.
Alejandro Zamilpa Álvarez, director of CIBIS, explained that since their objective is to find a solution to the main health problems of Mexicans, they have to identify which are the most frequent today, but also what will be the real challenges for the health system in the next 15 and 20 years; the most studied have been the central nervous system, dermatological problems, diabetes, obesity and cancer, which have had an impact on research that later becomes a technological development.
As of today, the CIBIS has requested a total of 32 patents, of which the Mexican Institute of Industrial Property (IMPI) has granted an average of 24, thus becoming the IMSS biomedical research center with the highest number of patents. .
With an express question, the doctor in chemistry mentioned that in order to complete a technological development that can be subject to a protection process, several stages of research have to be passed, the first one includes basic research in which possible solutions to the main most frequent health problems in Mexican society.
Each and every one of the CIBIS developments involves the use of standardized extracts of the active principles of plant species used in traditional Mexican medicine.
The second stage consists of the pharmaceutical design of each extract to generate the different presentations of the phytomedicines, the disciplines that participate in this stage, he explained, are Toxicology and Pharmacokinetics that help determine the safety, distribution and elimination of these medicines.
The idea culminates in clinical trials that allow them to demonstrate the safety and therapeutic efficacy of these phytomedicines -medicines of plant origin made with standardized extracts-.
Biotechnology, said the researcher, helps them to guarantee the source of raw material to obtain a uniform production procedure for plant species or their active principles.
So far, CIBIS research has only directly benefited volunteer patients who have participated in its clinical trials; However, when the institution licenses the exploitation of these patents or decides to use them to generate its own treatments, Mexican society in general will benefit.
Some of the patents registered have been: The use of active principles to make phytomedicines, as in the case of Galphimina B, which is used to produce anxiolytic drugs, or steroidal saponin SC-2, which has demonstrated therapeutic efficacy and safety in treatment from yeast infection (yeast infection).
The use of plant species such as Solanum chrysotrichum and Mimosa tenuiflora to make phytomedicines that help treat dermatological diseases and the gastric system, respectively, has also been protected.
Pharmaceutical preparations and extraction methods to obtain active principles have also been the subject of patenting, as well as the biotechnological processes that allow obtaining extracts and active principles and also the extracts stabilization procedures.
Most technological developments include a rigorous collaborative process between biologists, pharmacologists, chemists, biotechnologists and physicians, as well as external collaborations with specialized herbarium taxonomists, for this reason, the number of inventors for each patent ranges from three to seven researchers. .
Although for the CIBIS each of the patents has been a great achievement by involving long years of research, they have a special case of a Galphimia glauca patent that has even been the subject of several awards in the area of innovation.
The CIBIS is made up of an average of eight researchers.